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Abstract
Background: Magnetic resonance imaging (MRI) may guide breast cancer surgery by measuring residual tumor
size post-neoadjuvant chemotherapy (NAC). Accurate measurement may avoid overly radical surgery or reduce the
need for repeat surgery. This individual patient data (IPD) meta-analysis examines MRI’s agreement with pathology
in measuring the longest tumor diameter and compares MRI with alternative tests.
Methods: A systematic review of MEDLINE, EMBASE, PREMEDLINE, Database of Abstracts of Reviews of Effects,
Heath Technology Assessment, and Cochrane databases identified eligible studies. Primary study authors supplied
IPD in a template format constructed a priori. Mean differences (MDs) between tests and pathology (i.e. systematic
bias) were calculated and pooled by the inverse variance method; limits of agreement (LOA) were estimated. Test
measurements of 0.0 cm in the presence of pathologic residual tumor, and measurements >0.0 cm despite pathologic
complete response (pCR) were described for MRI and alternative tests.
Results: Eight studies contributed IPD (N = 300). The pooled MD for MRI was 0.0 cm (LOA: +/−3.8 cm). Ultrasound
underestimated pathologic size (MD: −0.3 cm) relative to MRI (MD: 0.1 cm), with comparable LOA. MDs were similar for
MRI (0.1 cm) and mammography (0.0 cm), with wider LOA for mammography. Clinical examination underestimated
size (MD: −0.8 cm) relative to MRI (MD: 0.0 cm), with wider LOA. Tumors “missed” by MRI typically measured 2.0 cm or
less at pathology; tumors >2.0 cm were more commonly “missed” by clinical examination (9.3 %). MRI measurements
>5.0 cm occurred in 5.3 % of patients with pCR, but were more frequent for mammography (46.2 %).
Conclusions: There was no systematic bias in MRI tumor measurement, but LOA are large enough to be clinically
important. MRI’s performance was generally superior to ultrasound, mammography, and clinical examination, and it
may be considered the most appropriate test in this setting. Test combinations should be explored in future studies.
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Background
Magnetic resonance imaging (MRI) has been proposed to
have a role in guiding breast cancer surgery by measuring
the size of residual tumor after neoadjuvant chemotherapy
(NAC), and has been shown to have high sensitivity for
detecting residual disease [1]. Given that guidelines rec-
ommend assessment of the largest tumor diameter [2],
estimation of the largest diameter by MRI may guide deci-
sions about whether subsequent mastectomy or breast
conserving surgery (BCS) should be attempted, as well as
assist in planning resection to achieve clear margins in
BCS. Underestimation of tumor size may therefore lead to
involved surgical margins and repeat surgery; overesti-
mation may lead to overly radical surgery (including mast-
ectomy when BCS may have been possible), and poorer
cosmetic and psychosocial outcomes [3].
Tumor size measurement is subject to potential errors,
and both tumor characteristics and imaging limitations
may differentially affect the measurement accuracy of tests
used for this purpose. MRI may over- or underestimate
tumor size due to artefacts such as partial volume effects
[4] or disruptions to signal intensity from marker place-
ment [5]. Tumors may not be well visualised by mammog-
raphy in patients with dense breasts [6] or multifocal
cancer [7]. Ultrasound (US) measurements may be com-
promised by unclear margins [8], acoustic shadowing [9]
or limitations in the field of view [10]. Imaging modalities
also differ in their ability to visualise ductal carcinoma in
situ (DCIS) [11]. The inherent pliability of breast tissue
also means that tumor dimensions may vary depending
on patient positioning [12]; therefore, differences in mea-
surements undertaken in upright (mammography), supine
(US) and prone positions (MRI) may arise. Furthermore,
the effects of NAC may introduce greater bias in residual
tumor measurement relative to the preoperative setting:
reactive inflammation, fibrosis or necrosis may be difficult
to distinguish from residual tumor [13], and measurement
errors may be additive when tumors regress as multiple,
scattered deposits [2].
While many studies have sought to assess the relative
ability of MRI and other tests to estimate tumor size
after NAC, conclusions have been hampered by small
sample sizes and inadequate statistical methods. A previ-
ous study-level meta-analysis demonstrated that mis-
leading conclusions about the accuracy of MRI may
result from inappropriate analytic methods that do not
measure agreement between clinical measures (e.g. Pear-
son or Spearman correlation coefficients) [14]. However,
that meta-analysis was limited in its ability to estimate
the agreement between MRI and pathologic measure-
ments, and to compare MRI with alternative tests, due
to numerous shortcomings in the available data. For
example, inconsistencies in measurement between studies,
such as the inclusion or exclusion of residual ductal
carcinoma in situ (DCIS) in pathologic tumour measure-
ments, may differentially affect the measurement accuracy
of MRI and other tests, and also limit the clinical applic-
ability of pooled estimates. Comparison of MRI and other
tests was also hampered by the tests being reported for
different (or, at best, overlapping) patient groups, for which
test performance may vary. Furthermore, a fundamental
limitation was that assessing the validity of assumptions
underlying the recommended statistical methods (mean
differences and limits of agreement [15]) was often not
possible due to inadequate reporting.
To address those limitations, we investigated agree-
ment between MRI-measured and pathologic tumor size
after NAC in an individual patient data (IPD) meta-
analysis of a large number of breast cancer patients,
using appropriate methods for evaluating the agreement
between measurements [15]. Key differences between
this and the previous study-level meta-analysis are sum-
marised in Additional file 1: Appendix 1. The IPD meth-
odology allowed us to standardise tumor measurements
to include invasive cancer only, explore agreement only
when residual tumor is truly present, and describe MRI
measurement errors in detail. In addition, our study
extended previous work by exploring agreement by char-
acteristics that have been suggested to contribute to in-
accurate measurement (NAC agents and HER2 status)
[16, 17], and examining MRI’s agreement compared with
and in addition to alternative tests (US, mammography,
clinical examination) when the tests were conducted in
the same patients [18].
Methods
Identification of studies
A systematic literature search up to February 2011 was
undertaken to identify studies of MRI for measuring re-
sidual tumor after NAC. MEDLINE and EMBASE were
searched via EMBASE.com; PREMEDLINE, Database of
Abstracts of Reviews of Effects, Heath Technology As-
sessment, and Cochrane databases were searched via
Ovid. Search terms linked MRI with breast cancer and
response to NAC. Keywords and medical subject head-
ings included ‘breast cancer’, ‘nuclear magnetic reson-
ance imaging’, ‘MRI’, ‘neoadjuvant’, and ‘response’. The
full search strategy has been reported previously [1, 19].
Reference lists were also searched and content experts
consulted to identify additional studies.
Review of studies and eligibility criteria
Abstracts were screened for eligibility by one author
(MLM); a sample of 10 % was assessed independently
(NH) to ensure consistent application of eligibility criteria.
There were no changes to eligibility criteria or coding
schemes based on the independent assessment. Eligible
studies enrolled ≥15 patients with newly diagnosed breast
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cancer undergoing NAC, with MRI and at least one other
test (US, mammography, clinical examination) after NAC
to assess residual tumor size (longest diameter) prior to
surgery.
Potentially eligible citations were reviewed in full
(MLM or NH). The screening and inclusion process is
summarised in Additional file 1: Appendix 2.
Individual patient data
A research protocol and database template were drafted a
priori, specifying the study rationale and objectives, IPD
requirements, and planned statistical analyses (Additional
file 1: Appendix 3). Those documents were forwarded to
the authors of eligible studies with an invitation to partici-
pate in the IPD meta-analysis, with email follow-up if no
response was received.
For each participating study, data irregularities were
discussed with the authors. Non-numeric tumor mea-
surements were treated as missing data. Observations
with missing pathologic measurements were excluded.
Pathologic measurements considered residual invasive
components only; therefore, the definition of pathologic
complete response (pCR) was standardised across stud-
ies as the absence of residual invasive cancer, with or
without the presence of DCIS (i.e. a pathologic measure-
ment of 0.0 cm) [20].
Statistical analysis
For individual studies, Bland-Altman scatterplots of the
differences between measurements by the relevant tests
and pathology (vertical axis) and their mean (horizontal
axis) were constructed. Plots were examined to assess
whether the differences were normally distributed and in-
dependent from the underlying size of the measurements
[15]. Scatterplots of log-transformed measurements were
also constructed to assess whether underlying relation-
ships were improved. Preliminary mixed linear models
(PROC MIXED in SAS) of the difference between mea-
surements by their mean, and pathologic size by MRI size,
were unstable and are not reported.
For patients with residual tumor at pathology, meas-
urement biases were estimated as the absolute mean
differences (MDs) between MRI, comparator tests and
pathology; the associated 95 % limits of agreement (LOA)
were also calculated for each study [15]. Relative MDs
were derived by exponentiation of the difference of log-
transformed measurements. MDs were pooled by the
inverse variance method using RevMan 5.2. A fixed effect
was assumed unless statistically significant heterogeneity
was present, as assessed by the Cochrane Q statistic. The
extent of heterogeneity was quantified by the I2 statistic
[21]. To estimate the 95 % LOA for a pooled MD, a
pooled variance was computed under the assumption that
the variance of the differences was equal across studies.
The pooled variance was calculated as the weighted average
of these within-study variances, weighted by the corre-
sponding degrees of freedom for each study (i.e. an exten-
sion of the approach used for a two sample t-test [22]).
In addition, test measurements of 0.0 cm in the pres-
ence of pathologic residual tumor, and measurements
>0.0 cm despite pCR were described for MRI and com-
parator tests. Exact 95 % confidence intervals for propor-
tions were computed (SAS version 9.2). Paired differences
between tests were tested with McNemar’s test. Differ-
ences in characteristics between patients with and without
tumor measurements by comparator tests were compared
with independent samples t-tests for continuous variables
and with chi-squared or Fisher’s exact tests for categorical
variables.
All tests of statistical significance were two-sided. Ex-
cept for tests of heterogeneity (p < 0.10), the level chosen
for statistical significance was p < 0.05; p ≤ 0.10 was con-
sidered to represent weak evidence of a difference [23].
Results
Study characteristics
A total of 2108 citations were identified. Twenty-four stud-
ies (1228 patients) were eligible for inclusion [13, 24–46];
eight of those contributed IPD to this analysis (300 pa-
tients) [13, 24, 25, 29, 34, 38, 44, 46] (Additional file 1:
Appendix 2). Agreement between residual tumor size
by tests and pathology was compared for MRI and US
in five studies [13, 29, 34, 38, 46]; MRI and mammog-
raphy in four studies [13, 24, 34, 38]; and MRI and clin-
ical examination in three studies [13, 24, 25]. For one
study [44], MRI and pathologic measurements were
provided but data for alternative tests were unavailable.
Characteristics of the included studies are presented in
Table 1. Included studies were generally representative of
the broader population of studies reported previously,
based qualitative comparison of aggregate descriptive char-
acteristics [14]. However, patients in this analysis were more
likely to have had T3 tumors or stage III disease; were more
commonly treated with anthracycline-taxane-based NAC;
and had a shorter time between MRI and surgery.
Technical characteristics of MRI are presented in
Additional file 1: Appendix 4. The majority of studies
used dynamic contrast-enhanced MRI (88 %) with a 1.5-T
magnet (75 %). Dedicated bilateral breast coils were used
in all studies reporting the coil type. All studies providing
detail on contrast employed gadolinium-based materials,
most commonly gadopentetate dimeglumine (62 %), at
the standard dosage of 0.1 mmol/kg body weight (75 %).
Pathology from surgical excision was the reference
standard for all patients in all but one study [34], where
pCR was verified by localisation biopsy in two cases
(0.7 % of all patients).
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Table 1 Summary of cohort, tumour, treatment and reference standard characteristics of studies included in the individual patient
data analysis
Study level estimates
Variable Patients (%) Median IQR Range
Cohort characteristics
N patients with MRI (8 studies) 300 (NA) 36 28 – 50 13 – 59
Recruitment mid-point (year) (4 studies) 144 (NA) 2003 2001 – 2005 2001 – 2006
Age, mean or median (years) (8 studies) 300 (NA) 47 46 – 48 43 – 49
Menopausal status (%)a (2 studies)
Pre 51 (72.9) 64.6 60.4 – 68.8 60.4 – 68.8
Peri/post 19 (27.1) 25.0 18.8 – 31.2 18.8 – 31.2
Tumour characteristics
Clinical size, mean or median (cm)a (4 studies) 136 (NA) 4.6 4.2 – 6.6 4.0 – 8.2
T stage (%)a (4 studies)
T1 5 (2.9) 2.9 1.0 – 5.0 0.0 – 6.2
T2 62 (35.8) 43.0 23.9 – 50.3 6.2 – 56.2
T3 78 (45.1) 43.6 38.3 – 49.1 37.5 – 50.0
T4 28 (16.2) 9.8 0.0 – 30.6 0.0 – 41.7
Stage (%)a (6 studies)
I 1 (0.5) 0.0 0.0 – 0.0 0.0 – 3.1
II 131 (59.0) 66.1 45.0 – 78.0 27.1 – 86.7
III 83 (37.4) 32.3 22.0 – 37.5 0.0 – 72.9
IV 7 (3.2) 0.0 0.0 – 0.0 0.0 – 17.5
Histology (%)a (6 studies)
IDC 191 (84.1) 86.2 74.2 – 87.8 68.8 – 90.0
ILC or IDC/ILC 19 (8.4) 9.8 5.1 – 10.0 4.9 – 18.8
Other 17 (7.5) 7.9 4.0 – 12.5 0.0 – 16.1
Nodal status (%)a (4 studies)
Positive 109 (72.2) 71.0 62.5 – 80.6 56.2 – 87.8
Negative 42 (27.8) 29.0 19.4 – 37.5 12.2 – 43.8
ER (%)a (5 studies)
Positive 113 (60.1) 62.5 60.0 – 64.4 45.0 – 69.2
Negative 73 (38.8) 37.5 32.2 – 40.0 15.4 – 55.0
Unknown or NR 2 (1.1) 0.0 0.0 – 0.0 0.0 – 3.4
PR (%)a (4 studies)
Positive 71 (44.9) 41.2 32.9 – 49.8 30.8 – 52.1
Negative 84 (53.2) 51.5 47.5 – 59.4 48.5 – 65.0
Unknown or NR 3 (1.9) 1.0 0.0 – 2.7 0.0 – 3.4
HER2 (%) (3 studies)
Positive 42 (28.8) 29.2 22.5 – 33.9 22.5 – 33.9
Negative 97 (66.4) 62.5 61.0 – 77.5 61.0 – 77.5
Unknown or NR 7 (4.8) 5.1 0.0 – 8.3 0.0 – 8.3
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MRI when residual tumor present at pathology
Figure 1a describes the size of residual tumor present at
pathology (N = 243) that was “missed” by MRI (i.e. MRI
tumor measurements of 0.0 cm). Patients for whom MRI
truly detected residual tumor (i.e. measurements > 0.0 cm)
are also included in the column labelled “not applicable”
(N/A). Pathologic measurements of tumors “missed” by
MRI ranged between 0.1-11.0 cm (median = 0.6 cm), and
measured 0.1-1.0 cm for 12 patients (4.9 %); 1.1-2.0 cm
for four patients (1.6 %); 2.1-3.0 cm for one patient
(0.8 %); and >7.0 cm for one patient (0.8 %).
Study-specific Bland-Altman plots, MDs and LOA be-
tween MRI and pathology are presented in Additional
file 1: Appendix 5. The plots suggested a tendency in
some studies for larger differences with increasing tumor
size; underlying relationships were not uniformly im-
proved by log transformation (Additional file 1: Appendix
5). Similar relationships were also apparent for US, mam-
mography and clinical examination (Additional file 1: Ap-
pendices 6–8). Analyses of absolute differences between
tests and pathology are reported here; analyses of relative
(log) differences were comparable, and are presented in
Additional file 1: Appendices 9–10.
Meta-analysis of MDs between MRI and pathology
(Table 2; Additional file 1: Appendix 11) showed no sys-
tematic bias in MRI’s estimation of pathologic tumor size
(pooled MD= 0.0 cm [95 % CI: −0.1-0.2 cm]), with no
evidence of heterogeneity (I2 = 0 %). Scatterplots showed
both over- and underestimation by MRI (Additional file 1:
Appendix 5). Pooled LOA indicated that 95 % of patho-
logic measurements fall between +/−3.8 cm of the MRI
measurement.
MRI versus US
In 123 patients with pathologic residual tumor and paired
measurements by MRI and US, distributions of pathologic
size were comparable when either test measured 0.0 cm;
tumors “missed” by each test typically measured ≤2.0 cm,
with one MRI measurement in the range of 2.1-3.0 cm
(Fig. 1b).
Pooled MDs showed a tendency for MRI to slightly over-
estimate pathologic tumor size (MD= 0.1 cm) with no evi-
dence of heterogeneity (I2 = 0 %) (Table 2; Additional file 1:
Appendix 11). A larger tendency for underestimation by
US (MD= −0.3 cm) was observed with substantial hetero-
geneity (Q = 13.11, df = 4, p = 0.01; I2 = 69 %); the pooled
MD did not change when a fixed or random effect(s) were
assumed. Pooled differences between MRI and US showed
only weak evidence of a difference between the measure-
ments (assuming random effects, p = 0.10). Pooled LOA
were comparable for MRI (+/−2.8 cm) and US (+/−2.6 cm)
(Table 2), with both over- and underestimation observed
Table 1 Summary of cohort, tumour, treatment and reference standard characteristics of studies included in the individual patient
data analysis (Continued)
Treatment
NAC regimen (%)a (8 studies)
Anthracycline-based 115 (38.1) 9.3 0.0 – 77.6 0.0 – 100.0
Antracycline-taxane-based 181 (59.9) 88.1 17.4 – 100.0 0.0 – 100.0
Other 6 (2.0) 0.0 0.0 – 2.5 0.0 – 100.0
Trastuzumab (%)a (3 studies)
Trastuzumab used 29 (19.6) 7.3 2.1 – 42.4 2.1 – 42.4
Trastuzumab not used 119 (80.4) 92.7 57.6 – 97.9 57.6 – 97.9
Type of surgery (%)a (8 studies)
BCS 132 (43.1) 50.3 37.6 – 55.9 6.2 – 59.4
Mastectomy 172 (56.2) 57.2 44.1 – 63.8 34.4 – 93.8
No surgery 2b (0.7) 0.0 0.0 – 0.0 0.0 – 6.2
Reference standard
Type of reference standard (%) (8 studies)
Pathology 298 (99.3) 100.0 100.0 – 100.0 93.8 – 100.0
Other 2b (0.7) 0.0 0.0 – 0.0 0.0 – 6.2
Time from MRI to surgery, mean or median/estimate (days) (6 studies) 228 (NA) 16 12 – 25 7 - 28
Prevalence of pCR (%) (8 studies) 300 (NA) 19.0 15.5 – 23.4 7.1 – 27.5
BCS breast conserving surgery, DCIS ductal carcinoma in situ, ER estrogen receptor, HER2 human epidermal growth factor receptor 2, IDC invasive ductal
carcinoma, ILC invasive lobular carcinoma, IQR inter-quartile range, MRI magnetic resonance imaging, NA not applicable, NAC neoadjuvant chemotherapy, NR not
reported, pCR pathologic complete response, PR progesterone receptor
aCalculation of values based on total number of patients enrolled, a minority of whom may not have contributed data to this analysis
bLocalisation biopsy showed the absence of residual tumour (i.e. pathologic measurement of 0.0 cm)
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for both tests (Additional file 1: Appendices 5–6). Combin-
ing MRI and US measurements by taking their mean re-
sulted in slight underestimation (MD= −0.1 cm), with a
small reduction in LOA compared with either test alone
(+/−2.3 cm).
US measurements were not possible (due to large or
diffuse lesions, or acoustic shadowing on US images) in
14 patients (10.2 % of patients with MRI). Patients with-
out US had significantly larger tumors at pathology
(mean 5.3 vs 2.0 cm; p = 0.003); were more likely to be
diagnosed with advanced (stage III/IV) disease (83.3 %
vs 32.3 %; p = 0.001); were less likely to have received
taxane-based NAC (38.5 % vs 74.0 %; p = 0.02); and were
more likely to have undergone mastectomy (78.6 % vs
46.3 %; p = 0.02) than patients with US measurements.
For the 14 patients without US, the MD between MRI
and pathology was −1.5 cm (95 % CI: −3.1-0.1 cm) and
the LOA were +/−6.0 cm (Table 2).
MRI versus mammography
For patients with pathologic residual tumor and mea-
surements by MRI and mammography (N = 78), tumors
with measurements of 0.0 cm by the tests typically
measured ≤2.0 cm at pathology (Fig. 1c); however, the
proportion of “missed” tumors within that range was
higher for mammography (23.1 %) than MRI (10.3 %;
p = 0.002). Mammography “missed” two tumors meas-
uring >6.0 cm; one of those (measuring 11.0 cm) also
measured 0.0 cm on MRI.
Pooled MDs showed a tendency for MRI to slightly over-
estimate pathologic tumor size (MD= 0.1 cm) with no evi-
dence of heterogeneity (I2 = 0 %) (Table 2; Additional file 1:
Appendix 11). No systematic bias was observed for
mammography (MD = 0.0 cm), but moderate hetero-
geneity was present (I2 = 39 %). No evidence of a differ-
ence between MRI and mammographic measurements
was observed (assuming a fixed effect, p = 0.59). Pooled
LOA for mammography (+/−5.0 cm) were wider than for
MRI (+/−4.1 cm) (Table 2); over- and underestimation
were observed for both tests (Additional file 1: Appendices
5 and 7). Combining MRI and mammography by taking
their mean did not improve the MD (0.1 cm) or LOA
(+/−4.2 cm) over MRI alone.
Tumor measurements by mammography were not
possible (due to dense breasts, tumor margins no longer
being assessable, or tumor not being visible) for 25 pa-
tients (24.3 % of patients with MRI). Patients without
mammography were significantly younger (mean 42 vs
47 years; p = 0.03) than patients with mammographic
measurements. For those patients, the MD between MRI
and pathology was 0.0 cm (95 % CI −0.7-0.7 cm) and the
LOA were +/−3.5 cm (Table 2).
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(c) MRI versus mammography (N=78)
0
10
20
30
40
50
60
70
0
10
20
30
40
50
60
70
80
90
N/A* 0.1-1.0 1.1-2.0 2.1-3.0 3.1-4.0 4.1-5.0 5.1-6.0 6.1-7.0 > 7.0
N
u
m
b
er o
f p
atien
rs w
ith
 resid
u
al tu
m
o
r (N
)P
er
ce
n
t o
f 
p
at
ie
tn
s 
w
it
h
 r
es
id
u
al
 t
u
m
o
r 
(%
)
Pathologic measurement of residual tumor when MRI or mammography 
measure 0.0 (cm)
MRI
Mammography
(d) MRI versus clinical examination (N=107)
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Fig. 1 Pathologic size (cm) of tumor “missed” by MRI for: a all patients with residual tumor (N = 243); and compared with b US (N = 123),
c mammography (N = 78), and d clinical examination (N = 107). MRI = magnetic resonance imaging; N/A = not applicable; US = ultrasound.
*Pathology and test(s) measure > 0.0 cm (i.e. residual tumor was not “missed” by MRI or alternative tests).
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MRI versus clinical examination
For 107 patients with pathologic residual tumor and
paired measurements by MRI and clinical examination,
tumors “missed” by MRI measured ≤2.0 cm at pathology
in all but one case (0.9 %), but 10 patients (9.3 %) with
measurements of 0.0 cm by clinical examination had
pathologic residual tumor >2.0 cm (p = 0.003). Both tests
“missed” one tumor with a pathologic measurement of
11.0 cm (Fig. 1d).
Pooled MDs showed no systematic bias in MRI’s esti-
mation of pathologic tumor size (MD = 0.0 cm) with no
evidence of heterogeneity (I2 = 0 %) (Table 2; Additional
file 1: Appendix 11). A relatively large tendency for under-
estimation by clinical examination (MD= −0.8 cm) was
observed with moderate heterogeneity (Q = 4.65, df = 2,
p = 0.1; I2 = 57 %); the pooled MD assuming a fixed effect
was similar (MD = −0.7 cm). Pooled differences between
MRI and clinical examination showed measurements by
clinical examination to be significantly lower than MRI
(assuming random effects, p = 0.006). Pooled LOA for
clinical examination (+/−5.1 cm) were wider than for MRI
(+/−4.2 cm) (Table 2); over- and underestimation were ob-
served for both tests (Additional file 1: Appendices 5 and
8). Combining MRI and clinical examination by taking
their mean did not substantially improve the MD
(−0.2 cm) or LOA (+/− 4.1) over MRI alone.
Estimation of tumor size by clinical examination was
not possible for three patients. In one patient each, MRI
correctly estimated, underestimated (−0.1 cm) and over-
estimated (0.8 cm) pathologic tumor size.
MRI measurement by NAC agents and HER2 status
In 88 patients treated with non-taxane-based NAC from
three studies [25, 29, 46], the pooled MD showed slight
underestimation by MRI (−0.1 cm) with no evidence of
heterogeneity (I2 = 0 %). Data from 63 patients treated
with taxane-containing NAC in those studies showed a
tendency for overestimation by MRI (MD = 0.2 cm) with
no evidence of heterogeneity (I2 = 0 %) (Additional file 1:
Appendix 12). Pooled LOA in patients treated with non-
taxane-based NAC (+/−4.3 cm) were wider than for pa-
tients treated with taxanes (+/−2.8 cm). When three add-
itional studies [13, 24, 38] using only taxane-containing
NAC were included in pooled estimates (six studies,
152 patients in total), the MD did not change (0.2 cm;
I2 = 0 %), but LOA were higher (+/−3.9 cm).
Table 2 Pooled absolute differences (cm) (fixed effect unless noted) and limits of agreement for studies and patients comparing the
respective tests
N (studies) N (patients) Pooled MD (cm) (95 % CI) I2 LOA (cm)
All studies and patients
MRI vs pathology 8 243 0.0 (−0.1, 0.2) 0 % +/−3.8
Studies of MRI vs US
MRI vs pathology 5 123 0.1 (−0.2, 0.3) 0 % +/− 2.8
US vs pathologya 5 123 −0.3 (−0.6, 0.1) 69 % +/− 2.6
MRI and US (mean) vs pathology 5 123 −0.1 (−0.3, 0.1) 16 % +/− 2.3
MRI vs USa 5 123 0.3 (−0.1, 0.7) 81 % NA
MRI vs pathology (patients without US)b 3 14 −1.5 (−3.1, 0.1) NA +/− 6.0
Studies of MRI vs mammography
MRI vs pathology 4 78 0.1 (−0.1, 0.3) 0 % +/− 4.1
Mammography vs pathology 4 78 0.0 (−0.3, 0.4) 39 % +/− 5.0
MRI and mammography (mean) vs pathology 4 78 0.1 (−0.1, 0.4) 21 % +/− 4.2
MRI vs mammography 4 78 0.1 (−0.2, 0.4) 0 % NA
MRI vs pathology (patients without mammography)b 3 25 0.0 (−0.7, 0.7) NA +/− 3.5
Studies of MRI vs clinical examination
MRI vs pathology 3 107 0.0 (−0.2, 0.3) 0 % +/− 4.2
Clinical examination vs pathologya 3 107 −0.8 (−1.5, −0.1)* 57 % +/− 5.1
MRI and clinical examination (mean) vs pathology 3 107 −0.2 (−0.5, 0.1) 9 % +/− 4.1
MRI vs clinical examinationa 3 107 0.9 (0.2, 1.5)* 56 % NA
MRI vs pathology (patients without clinical examination)b 2 3 NAc NAc NAc
CI confidence interval, LOA limits of agreement, MD mean difference, MRI magnetic resonance imaging, NA not applicable, US ultrasound
*p < 0.01
aRandom effects
bPatients without comparator test combined as a single data set. Pooled meta-analysis not undertaken
cNot calculated due to small number of patients
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Pooled MDs from three studies [24, 29, 46] showed com-
parable overestimation by MRI in HER2- (MD = 0.2 cm;
N = 97) and HER2+ patients (MD= 0.3 cm; N = 42), with
no evidence of heterogeneity for either group (I2 = 0 %)
(Additional file 1: Appendix 12). Pooled LOA were also
similar (+/−4.3 cm for HER2- patients; +/− 4.2 cm for
HER2+ patients).
MRI when no residual tumor at pathology (pCR)
For all studies combined, pCR was present in 57/300 pa-
tients (19.0 % [95 % CI: 14.7-23.9 %]). Study-specific
rates of pCR ranged from 7.1-27.5 % (median = 19.1 %).
MRI tumor measurements > 0.0 cm for patients with
pCR are presented in Fig. 2a (measurements of 0.0 cm
are also described, representing true identification of
pCR by MRI). MRI measurements >0.0 cm ranged
between 0.3-6.1 cm (median = 2.0 cm), and measured
0.1-1.0 cm for seven patients (12.3 %); 1.1-2.0 cm for six
patients (10.5 %); 2.1-5.0 cm for five patients (8.8 %);
and >5.0 cm for three patients (5.3 %).
MRI versus alternative tests in assessing pCR
Figure 2b–d present the distribution of MRI tumor mea-
surements > 0.0 cm for patients with pCR compared with
measurements by US (N = 35), mammography (N = 13,
excluding five patients with MRI but no mammographic
measurement), and clinical examination (N = 18). Large
(>5.0 cm) measurement errors in the presence of pCR
were more common by mammography (46.2 %) than MRI
(15.4 %; p = 0.05); both large MRI measurements also
measured >5.0 cm on mammography. The proportion of
large MRI measurement errors was not significantly differ-
ent from US or clinical examination.
For 5/18 patients (27.8 %) with no mammographic
measurement (due to dense breasts or tumor margins
not being assessable post-NAC), MRI measurements
>0.0 cm occurred in three patients, ranging between
1.1–2.0 cm.
Discussion
In the neoadjuvant setting, accurate measurement of re-
sidual malignancy may assist in guiding surgical manage-
ment of breast cancer. While past research focussed on
the accuracy of MRI to detect the absence of residual
tumor (pCR) as a predictor of overall and disease-free sur-
vival [1], MRI measurements of tumor size have the po-
tential to inform decisions about surgical extent (e.g. BCS
versus mastectomy). Our IPD meta-analysis assessed the
agreement between MRI and pathologic tumor measure-
ments after NAC. Pooled MDs between MRI and path-
ology indicated that there was no systematic bias in MRI’s
(a) MRI alone (N with pCR =57)
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Fig. 2 MRI measurements (cm) for: a all patients with pCR (N = 57); and compared with measurements by b US (N = 35), c mammography
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estimation of tumor size when residual tumor was pre-
sent. Measurement variability for agreement was lower
than estimated by our previous study-level analysis [14];
however, both over- and underestimation by MRI were
observed, and LOA (+/−3.8 cm) show that substantial dis-
agreement with pathology is possible. MRI measurement
errors within that range may be of clinical importance in
terms of their implications for the choice of treatment.
The IPD methodology used in this analysis allowed for
measurement errors to be explored in greater detail than
that permitted by study-level analyses [14]. Tumors
“missed’ by MRI generally measured ≤2.0 cm at path-
ology; however, MRI measurements >5.0 cm occurred in
a small proportion of cases where pCR was achieved. Al-
though descriptive reporting of such overestimation was
not standard across included studies, one of the three
cases of MRI measurements >5 cm in the presence of
pCR observed in this data set was attributed to the pres-
ence of extensive DCIS. Other possible causes include
reactive inflammation, fibrosis or necrosis induced by
NAC [13]. Description of cases of large overestimation
in future studies would be valuable in guiding future
research and practice. Assuming that surgeons consider
the MRI-determined measurement when planning resec-
tion, such overestimation would lead to unnecessarily
large excision. Although those patients are likely to
benefit from improved disease-free and overall survival
conferred by pCR [47], they are less likely to benefit
from a reduction in surgical extent after NAC.
Comparisons of MRI and US in the same patients
showed similar LOA, suggesting comparable performance
by MRI and US when residual tumor is present (although
substantial heterogeneity for US reflects its operator de-
pendence [2]). However, contrary to our previous study-
level analysis [14], a small bias towards underestimation of
tumor size was found for US; clinical preference for either
slight overestimation (MRI) or underestimation (US) of
pathologic size should be considered in the choice of test.
Furthermore, our analysis extends previous work by sug-
gesting that considering the mean measurement of both
tests may further improve tumor measurement. Given
that studies may not have interpreted MRI blinded to US,
this result is likely to underestimate the value of combin-
ing the tests. Clinicians adopting this testing strategy
should be aware that the direction of MRI’s systematic
bias was reversed (slight underestimation) when the tests
were combined.
It is noteworthy that MRI did not estimate tumor size
as accurately in patients for whom US measurement was
not possible, with (on average) relatively large underesti-
mation and wide LOA. Tumor characteristics are likely
to have contributed to measurement being challenging
for both tests. Patients without US had larger tumors
(and consistent with this, were diagnosed with more
advanced disease and were more likely to have under-
gone mastectomy), reflecting limitations in the US field
of view [10]. The higher rate of non-taxane-based NAC
in that group may also have contributed to the larger
residual tumor size [48]. When planning resection, clini-
cians should note that although tumor measurement by
MRI may be possible for such patients, the potential for
size underestimation may lead to incomplete excision.
This analysis is the first to consider those patients separ-
ately, and directly compare MRI and US when measure-
ment by both tests can be undertaken. Our findings
highlight the importance of study authors reporting
MRI’s agreement with pathology separately for patients
with and without alternative tests [14, 18].
In patients with measurements by both MRI and mam-
mography, a systematic bias in estimating tumor size was
found only for MRI (slight overestimation); the larger
overestimation for mammography found in a previous
analysis (which included fewer studies comparing mam-
mography and MRI) [14] was not observed. However, the
difference between test measurements was small, and
mammography’s moderate heterogeneity, wider LOA, and
tendency to “miss” smaller tumors (≤2.0 cm) indicate
greater variability for agreement with pathology. Conse-
quently, combining MRI and mammography did not im-
prove tumor measurement compared with MRI alone. In
addition, a tendency for large mammographic measure-
ments in the presence of pCR suggests that mammog-
raphy may lead to overly radical surgery when pCR is
achieved. Mammographic tumor measurements were
frequently not possible due to breast density, reflected in
the younger age of those women [49]. These findings
therefore suggest that MRI would be the preferred test in
this setting.
Direct comparison of MRI and clinical examination
showed no systematic bias in MRI’s measurement of re-
sidual tumor; relatively large underestimation, moderate
heterogeneity and wider LOA for clinical examination
were observed, suggesting greater variability for agree-
ment with pathology. In addition, apart from one case,
tumors with pathologic measurements of >2.0 cm were
“missed” only by clinical examination, highlighting the
potential for inadequate resection if surgical planning
was based on clinical examination alone. While better
overall agreement between MRI and pathology suggest
that MRI is the more appropriate assessment method, it
is possible that a combination of US and clinical examin-
ation may be superior to either test individually [50], but
that testing strategy could not be explored in this ana-
lysis. The relative performance of test combinations
should be considered in future studies.
Data from single studies have suggested that under-
estimation by MRI is common in HER2- patients [16] or
those treated with taxane-containing regimens [17], but
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previous study-level meta-analyses were unable to fur-
ther explore the effect of these variables. Similar effects
were not observed in our IPD analysis. For patients with
data available on HER2 status, MRI performed compar-
ably regardless of tumor biology. Although that analysis
was based on relatively few studies, the combined sam-
ple size is substantially larger than the previous study
exploring the effect of this variable, and the studies that
did not contribute data predate the routine testing of
HER2. Furthermore, contrary to previous reports, a
slight bias towards underestimation (and poorer overall
agreement with pathology) was found in patients treated
with non-taxane-based NAC. However, although more
detailed analyses were attempted, statistical models were
unstable and therefore the results presented are primar-
ily descriptive. Further exploration of the effect of these
characteristics on measurement accuracy is warranted in
large primary studies, controlling for the effect other
potentially important covariates.
Given that not all eligible studies contributed IPD to this
meta-analysis, selection bias may have been introduced.
Although studies in this analysis were similar in most re-
spects to the broader population of eligible studies [14], a
higher proportion of T3 tumors and stage III disease was
apparent. Other differences suggest that included studies
are more applicable to current practice (i.e. NAC with tax-
anes was more common), and less susceptible to changes
in tumor dimensions between MRI and pathologic meas-
urement (i.e. shorter interval between tests). Our IPD
analysis also included a larger number of studies than the
only previous (study-level) meta-analysis utilising appro-
priate statistical techniques to address this clinical ques-
tion [14] (see Additional file 1: Appendix 1).
Although MDs and LOA are the most methodologic-
ally appropriate measures of agreement between MRI
and pathology [15], there was no clear indication to con-
sider either absolute or relative differences between the
tests in our analysis. Plots of the data suggest that the
absolute MDs reported here are likely to be most applic-
able to mid-sized tumors, but may differ for small or
large residual cancers. However, analyses of absolute and
relative differences were comparable, and therefore in-
ferences about MRI and its performance compared to
alternative tests are likely to be robust.
Due to pCR being achieved in a minority of patients
(between 7.1 % and 27.5 % in the included studies),
analyses of measurement errors in the presence of pCR
are based on relatively small sample sizes and should
therefore be interpreted cautiously. Furthermore, to
standardise the definition of pCR across studies, this
analysis considered the presence of invasive cancer only.
This represents an advance in methods over previous
analyses by reducing the potential for heterogeneity and
improving the clinical applicability of pooled estimates.
However, tests may differ in their ability to visualise
DCIS or calcifications [11], and hence the accuracy of
MRI and alternative tests to measure those outcomes
may differ from our estimates. Our findings that alterna-
tive tests could not evaluate residual tumor in a propor-
tion of patients should also be interpreted with awareness
that corresponding data about non-evaluable tumors by
MRI were unavailable.
Conclusion
Our meta-analysis is the largest and most statistically
appropriate evaluation of the agreement between MRI
and pathologic residual tumor size post-NAC, and the
only meta-analysis on this topic using IPD methodology.
Our work suggests that there is no systematic bias in
MRI’s measurement of residual invasive tumor, but that
both over- and underestimation by MRI is possible, with
LOA large enough to be of clinical importance. MRI’s
performance was generally superior to that of US, mam-
mography, and clinical examination, and in light of those
findings, MRI may be considered the most appropriate
test in this setting. However, large MRI measurements
are possible in a small proportion of pCR cases, and
patient characteristics that render tumors non-evaluable
by US may contribute to inaccurate size measurements
by MRI; those potential disadvantages should be consid-
ered in the choice of test. Furthermore, it is possible that
a combination of US and clinical examination may be
superior to those tests individually, and such a testing
strategy has potential advantages over MRI in terms of
lower cost and greater accessibility. Combinations of
alternative tests, and their performance relative to MRI,
should be explored in future studies.
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